Table 3.

Number (%) of responders^a for selected efficacy variables at the study endpoint (full analysis set)

	Placebo	Mirabegron OCASb				Tolterodine ERb
		25 mg	50 mg	100 mg	200 mg	4 mg
Patients, n (%)c
Micturitions/24 h*	n = 166	n = 167	n = 167	n = 168	n = 166	n = 85
	32 (19.3)	48 (28.7)	46 (27.5)	55 (32.7)	50 (30.1)	16 (18.8)
Incontinence episodes/24 h*	n = 106	n = 99	n = 108	n = 111	n = 110	n = 53
	39 (36.8)	42 (42.4)	45 (41.7)	62 (55.9)	53 (48.2)	19 (35.8)
Urgency episodes (grade  ≥ 3)/24 h	n = 165	n = 167	n = 166	n = 168	n = 165	n = 85
	25 (15.2)	27 (16.2)	24 (14.5)	33 (19.6)	36 (21.8)	13 (15.3)
Nocturia episodes/24 h	n = 144	n = 145	n = 142	n = 141	n = 147	n = 72
	21 (14.6)	34 (23.4)	34 (23.9)	20 (14.2)	34 (23.1)	13 (18.1)

OCAS oral controlled absorption system, ER extended release

*p ≤ 0.05 based on a Mantel–Haenszel test to compare all treatment groups, except tolterodine

^aResponder definitions: micturitions, <8 micturitions/24 h; incontinence episodes, no episodes (patient became dry); urgency and nocturia episodes, no episodes of either

^bMirabegron and tolterodine were administered once daily (QD)

^cPercentages are based on the number of patients with available data at the endpoint